

ONLINE FIRST

Maternal Influenza Vaccination and Effect on Influenza Virus Infection in Young Infants

Angelia A. Eick, PhD; Timothy M. Uyeki, MD, MPH, MPP; Alexander Klimov, PhD; Henrietta Hall, MS; Raymond Reid, MD; Mathuram Santosham, MD; Katherine L. O'Brien, MD, MPH

Objective: To assess the effect of seasonal influenza vaccination during pregnancy on laboratory-confirmed influenza in infants to 6 months of age.

Design: Nonrandomized, prospective, observational cohort study.

Setting: Navajo and White Mountain Apache Indian reservations, including 6 hospitals on the Navajo reservation and 1 on the White Mountain Apache reservation.

Participants: A total of 1169 mother-infant pairs with mothers who delivered an infant during 1 of 3 influenza seasons.

Main Exposure: Maternal seasonal influenza vaccination.

Main Outcome Measures: In infants, laboratory-confirmed influenza, influenzalike illness (ILI), ILI hospitalization, and influenza hemagglutinin inhibition antibody titers.

Results: A total of 1160 mother-infant pairs had serum collected and were included in the analysis. Among infants, 193 (17%) had an ILI hospitalization, 412 (36%)

had only an ILI outpatient visit, and 555 (48%) had no ILI episodes. The ILI incidence rate was 7.2 and 6.7 per 1000 person-days for infants born to unvaccinated and vaccinated women, respectively. There was a 41% reduction in the risk of laboratory-confirmed influenza virus infection (relative risk, 0.59; 95% confidence interval, 0.37-0.93) and a 39% reduction in the risk of ILI hospitalization (relative risk, 0.61; 95% confidence interval, 0.45-0.84) for infants born to influenza-vaccinated women compared with infants born to unvaccinated mothers. Infants born to influenza-vaccinated women had significantly higher hemagglutinin inhibition antibody titers at birth and at 2 to 3 months of age than infants of unvaccinated mothers for all 8 influenza virus strains investigated.

Conclusions: Maternal influenza vaccination was significantly associated with reduced risk of influenza virus infection and hospitalization for an ILI up to 6 months of age and increased influenza antibody titers in infants through 2 to 3 months of age.

Arch Pediatr Adolesc Med. 2011;165(2):104-111.

Published online October 4, 2010.

doi:10.1001/archpediatrics.2010.192

Author Affiliations: Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (Drs Eick, Reid, Santosham, and O'Brien); Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia (Drs Uyeki and Klimov and Ms Hall). Dr Eick is now with the Armed Forces Health Surveillance Center, Silver Spring, Maryland.

INFLUENZA VIRUS ACTIVITY AND DISEASE severity varies from season to season; however, studies have consistently identified young children to be at high risk of influenza complications. Among healthy children younger than 5 years, annual influenza-associated hospitalization rates are approximately 100 per 100 000, while children with underlying medical conditions have rates of approximately 500 per 100 000 in the United States.¹⁻⁴

For editorial comment see page 179

Influenza virus infection in infants is generally more frequent among those aged 6 to 12 months than in the first 6 months of life, potentially owing to the protection conferred by maternal influenza an-

tibodies acquired transplacentally or through breastfeeding.⁵ However, during severe influenza seasons, morbidity and mortality rates among infants younger than 6 months have been reported to exceed those of older infants.⁶⁻¹¹

The US Advisory Committee on Immunization Practices recommends that pregnant women receive influenza vaccine because of the increased risk of influenza complications in pregnant women.⁴ Maternal influenza vaccination may also confer a benefit to infants born during influenza season, as they are ineligible for vaccination until 6 months of age.

Several studies have investigated the ability of maternally derived influenza-specific antibodies to protect infants from influenza virus infection and/or to reduce severity of illness.¹²⁻¹⁴ Findings among infants attributable to maternal influenza vaccination have included delayed onset of in-

fection, older age when infected, and 1 randomized trial showing a reduction in laboratory-confirmed influenza.

Navajo and White Mountain Apache children have rates of acute respiratory infection that are significantly higher than in the general US population.¹⁵⁻¹⁷ Because influenza vaccination of all pregnant women is recommended, a randomized clinical trial was not possible in the United States. Therefore, we conducted a nonrandomized, prospective, observational cohort study to evaluate the effect of seasonal influenza vaccination during pregnancy on influenza virus infection in infants compared with that of infants born to unvaccinated women.

METHODS

SETTING

The study was conducted on the Navajo and White Mountain Apache Indian reservations in the Southwest region of the United States. Health care is administered through the Indian Health Service, an agency of the federal government, or through the tribe; services are provided without fees to registered tribal members. Six Navajo hospitals (Chinle, Gallup, Fort Defiance, Shiprock, Tuba City, and Winslow) and 1 (Whiteriver) on the White Mountain Apache reservation participated in this study.

DESIGN

The study was conducted during 3 influenza seasons from November 2002 to September 2005. The enrollment periods for each year were December 1, 2002, to March 15, 2003; November 1, 2003, to March 8, 2004; and November 1, 2004, to March 15, 2005. Inclusion was restricted to mothers who delivered a healthy infant at 36 weeks' or later gestation during the enrollment periods. Eligible infants were aged 2 weeks or younger at enrollment.

RECRUITMENT

Mother-infant pairs were recruited after delivery at Indian Health Service hospitals on the Navajo or White Mountain Apache reservation either at the hospital or by home visit. Written informed consent was obtained from all mothers. For all subjects, the study began following delivery. The decision for influenza vaccination was made by the treating clinician and the pregnant woman; study personnel had no involvement in these decisions. We provided annual training/education to medical providers and the community regarding influenza vaccine recommendations and the purpose of the study. Prior to the study, less than 10% of eligible pregnant women received influenza vaccine. Donations of thimerosal-reduced inactivated influenza vaccine were made annually to the Indian Health Service hospitals to assure adequate supply for pregnant women.

DATA COLLECTION

Questionnaires were administered verbally at study enrollment and the end of the influenza season to collect information on demographics, breastfeeding status, potential influenza risk factors, and influenza vaccination status of all household members. The mother's medical record was reviewed for the period from first prenatal care visit to delivery for information on prenatal visits, illnesses, birth information, and the administration and timing of an influenza vaccine.

Surveillance for all medically attended illnesses in enrolled infants was conducted at Indian Health Service and nearby private

facilities during the influenza season, defined as November through April, for each year of the study or until the child reached 6 months of age (whichever came first). The primary outcome of interest was medically attended influenzalike illness (ILI). This outcome was defined as a medical visit with at least 1 of the following signs or symptoms reported: fever of 38.0°C or higher, diarrhea, or respiratory symptoms (including cough, runny nose, or difficulty breathing). Diarrhea was included in this definition because young infants can experience diarrhea with influenza virus infection.^{18,19} Daily active surveillance for ILI episodes included review of the clinic, emergency department, and inpatient pediatric ward logs. Parents were asked to contact research staff whenever their child had a medical visit for a respiratory, diarrheal, or febrile illness. Medical record reviews were conducted to identify missed episodes. When an ILI was documented in the infant's chart, information was collected on demographics, clinical symptoms, laboratory data including rapid influenza diagnostic testing and respiratory syncytial virus antigen testing, severity of illness, and diagnosis. A nasopharyngeal aspirate specimen for viral culture was obtained from infants with ILI within 72 hours of the medical visit.

Postpartum blood was obtained from the mother at or within 14 days of delivery. Umbilical cord blood was collected at delivery or, if unavailable, an infant blood specimen was collected within 14 days of delivery. Venous blood was obtained from the infant at 2 to 3 months and 6 months of age.

LABORATORY TESTING

Blood specimens were centrifuged at 3000 rpm for 10 minutes. The collected serum was divided into 2 aliquots of at least 0.5 mL each, frozen at -70°C, and shipped on dry ice to the Influenza Division, Centers for Disease Control and Prevention, for serological testing. Serum specimens were tested for influenza virus strain-specific antibodies using a standard hemagglutinin inhibition (HI) antibody assay. Specimens were tested for antibodies to influenza A and B vaccine strains and predominant circulating strains (if antigenically distinct from vaccine strains) for the corresponding season of interest: for the 2002-2003 season, A/New Caledonia/20/99 IVR-116 (H1N1) (A/New Cal; vaccine strain), A/Panama/2007/99 respiratory syncytial virus 17 (H3N2) (A/Panama; vaccine strain), A/Wyoming/3/2003 X-147 (H3N2) (A/Wyoming; predominant strain), B/Hong Kong/330/2001 (B/HK, vaccine strain from B/Victoria/2/87 lineage), and B/Sichuan/379/99 (B/Sichuan, circulating virus from B/Yamagata/16/88 lineage) were used; for the 2003-2004 season, the same as the 2002-2003 season were used except B/Brisbane/32/02 (B/Brisbane) instead of B/HK (B/Brisbane was dominant B/Victoria/2/87 lineage virus during the season); and for the 2004-2005 season, A/New Cal (H1N1 vaccine strain), A/Wisconsin/67/2005 (H3N2) (A/Wisconsin; predominant virus), B/Shanghai/361/02 (B/Shanghai, vaccine strain from B/Yamagata/16/88 lineage), and B/HK.

Nasopharyngeal aspirate specimens were mixed with viral transport media (Remel, Lenexa, Kansas), transported on wet ice, frozen and stored at -70°C, and shipped on dry ice to the University of Iowa for viral culture. Nasopharyngeal aspirate specimens were inoculated into Madin-Darby canine kidney cell culture, and viruses were detected by cytopathic effect and hemadsorption. Influenza virus infection was confirmed by indirect fluorescent antibody staining of infected cells.

STATISTICAL ANALYSIS

Maternal influenza vaccination status was based on medical record review or, if missing, by maternal report at enrollment. Hemagglutinin inhibition antibody titers of 1:40 or higher were

Table 1. Demographic Characteristics of Infants Born to Influenza-Vaccinated and Unvaccinated Mothers

	No. (%)		P Value ^a
	Unvaccinated (n=587)	Vaccinated (n=573)	
Sex			
Male	283 (48)	292 (51)	.34
Female	304 (52)	281 (49)	
Any household smokers			.25
Yes	102 (17) ^b	85 (15)	
No	484 (83) ^b	485 (85)	
Wood or coal burning stove			<.001
Yes	316 (54)	370 (65) ^b	
No	270 (46)	200 (35) ^b	
Any children in daycare			.28
Yes	30 (5) ^c	38 (7) ^c	
No	551 (95) ^c	528 (93) ^c	
Infant breastfed			.007
Yes	403 (74)	418 (81)	
No	140 (26)	97 (19)	
Gestational age, mean (SD), wk	39.3	39.3	.87
Birth weight, mean (SD), kg	3368	3347	.47

^aAll P values based on Fisher exact or χ^2 tests except for gestational age and birth weight, which used a t test.

^bOne missing value.

^cFive missing values.

considered evidence of immunity. Serum specimens with undetectable HI antibody titers were assigned a titer of 5.

The primary analytical outcome, laboratory-confirmed influenza, was defined as the first episode of ILI with (1) isolation of influenza virus from the nasopharyngeal aspirate specimen, (2) a 4-fold or greater rise in HI antibody in serum collected at 2 to 3 or 6 months compared with the previous serum specimen, indicating influenza virus infection during the time interval, or (3) a positive rapid influenza diagnostic test result with a medical diagnosis of influenza. The secondary analytic outcome of interest was ILI. Logistic regression was used to investigate the relationship between maternal influenza vaccination status, cord blood influenza HI antibody titers, and the occurrence of ILI or laboratory-confirmed influenza. In addition, ILI was further stratified by hospitalization status. Potential confounders such as daycare attendance, household smoking, wood or coal burning stove in the home, and breastfeeding were investigated. Relative risks with 95% confidence intervals not including 1.0 were considered significant.

To describe and compare influenza-specific antibodies, HI antibody titers were converted to a logarithmic scale. Geometric mean titers (GMTs) of influenza virus-specific antibody in postpartum, cord, 2 to 3-month, and 6-month serum specimens were calculated for influenza-vaccinated and unvaccinated mother-infant pairs. Comparisons between these 2 groups used a 2-sided t test. For each virus strain, the proportion of infants in each group with cord blood HI antibody titers of 1:40 or greater were calculated and compared using the Fisher exact test. Cord blood GMTs and the proportion of infants with cord blood HI antibody titers of 1:40 or greater were compared between mothers vaccinated in the second and third trimester using Wilcoxon rank sum and χ^2 tests, respectively.

Stata 8.1 (Stata Corp, College Station, Texas) software was used for the statistical analyses. The study was approved by the Navajo and White Mountain Apache tribes and the institutional review boards of the Navajo Nation, Phoenix Area Indian Health Service, and the Johns Hopkins Bloomberg School of Public Health.

Table 2. Relative Risk of Laboratory-Confirmed Influenza or ILI by Maternal Vaccination Status or Influenza-Specific Infant Cord Blood Antibody Titer^a

Predicting Variable	RR (95% CI)	
	Laboratory-Confirmed Influenza	ILI
	Maternal vaccination status	0.59 (0.37-0.93)
Cord blood HI antibody virus strain		
B/Sichuan ^b		
Log scale	0.62 (0.49-0.78)	1.04 (0.93-1.15)
Titer \geq 1:40	0.29 (0.16-0.53)	1.13 (0.85-1.51)
B/HK ^c		
Log scale	0.64 (0.42-0.97)	1.07 (0.92-1.25)
Titer \geq 1:40	0.54 (0.20-1.45)	1.18 (0.80-1.75)
A/New Cal ^{c,d}		
Log scale	0.68 (0.56-0.81)	1.02 (0.95-1.10)
Titer \geq 1:40	0.34 (0.20-0.59)	1.15 (0.90-1.46)
A/Panama ^c		
Log scale	0.50 (0.40-0.64)	0.95 (0.85-1.05)
Titer \geq 1:40	0.24 (0.13-0.44)	0.80 (0.60-1.07)
A/Wyoming ^d		
Log scale	0.52 (0.40-0.67)	0.96 (0.87-1.06)
Titer \geq 1:40	0.14 (0.07-0.30)	0.94 (0.70-1.25)
A/Wisconsin ^e		
Log scale	0.42 (0.18-0.99)	0.88 (0.69-1.11)
Titer \geq 1:40	...	0.98 (0.52-1.84)
B/Shanghai ^d		
Log scale	0.56 (0.39-0.82)	0.96 (0.83-1.12)
Titer \geq 1:40	0.29 (0.11-0.77)	0.94 (0.60-1.47)
B/Brisbane ^f		
Log scale	0.64 (0.51-0.82)	1.01 (0.90-1.14)
Titer \geq 1:40	0.26 (0.12-0.52)	1.12 (0.80-1.57)

Abbreviations: CI, confidence interval; ellipsis, analysis could not be performed; HI, hemagglutinin inhibition; ILI, influenza-like illness; RR, relative risk.

^aLog scale analysis is based on a continuous scale. Relative risk is the risk of influenza outcome for each log scale increase in cord blood antibody titer. Titer \geq 1:40 analysis compares the risk of influenza outcome among those with a cord blood titer of 1:40 or greater with the risk among those with a titer of less than 1:40.

^bCirculating strain during 2002-2003 season.

^cVaccine strains for the 2002-2003 and 2003-2004 seasons.

^dVaccine strains for the 2004-2005 season.

^ePredominating influenza A H3N2 virus for 2004-2005 season.

^fPredominating influenza B virus for 2003-2004 season.

RESULTS

POPULATION AND OUTCOMES

Overall, 1169 mother-infant pairs were enrolled in the study for the 2002-2003 (n=241), 2003-2004 (n=574), and 2004-2005 (n=354) influenza seasons. Of these, 1160 (99%) mother-infant pairs had at least 1 blood specimen collected and were included in the analysis. Forty-nine percent of infants (n=573) were born to mothers who received influenza vaccine during their pregnancy. Infants born to influenza-vaccinated and unvaccinated mothers were similar except that those born to vaccinated mothers were more likely to have a wood or coal burning stove in the house and to be breastfed (**Table 1**).

Of the 1160 infants, there were 908 ILI episodes; 193 children (17%) were hospitalized for ILI (84 had at least

Table 3. Relative Risk of Serologically Confirmed Influenza Virus Infection by Influenza-Specific Cord Blood HI Antibody Titer^a

Cord Blood HI Antibody Virus Strain	Influenza HI Antibody Titer With a 4-Fold Rise in Titer During the 2-3- or 6-mo Blood Draw							
	B/Sichuan (n=14)	B/HK (n=3)	A/New Cal, H1N1 (n=14)	A/Panama, H3N2 (n=29)	A/Wyoming, H3N2 (n=32)	A/Wisconsin, H3N2 (n=10)	B/Shanghai (n=6)	B/Brisbane (n=7)
B/Sichuan^b								
Log scale	0.36 (0.18-0.72)	0.48 (0.12-1.89)	0.87 (0.60-1.27)	0.62 (0.29-0.98)	0.78 (0.51-1.18)	0.95 (0.62-1.47)
Titer ≥1:40	0.60 (0.19-1.92)	0.41 (0.14-1.24)	0.57 (0.19-1.73)	0.65 (0.19-2.24)
B/HK^c								
Log scale	0.28 (0.03-2.59)	...	0.60 (0.21-1.73)	1.76 (0.38-8.21)	0.72 (0.16-3.11)	...
Titer ≥1:40	0.63 (0.06-7.04)
A/Newcal^{c,d}								
Log scale	0.71 (0.46-1.12)	0.68 (0.22-2.07)	0.18 (0.04-0.83)	0.52 (0.32-0.86)	0.44 (0.24-0.81)	0.75 (0.45-1.25)
Titer ≥1:40	0.56 (0.19-1.69)	0.98 (0.10-9.48)	...	0.41 (0.14-1.25)	0.08 (0.01-0.60)	0.48 (0.12-1.87)
A/Panama^c								
Log scale	0.57 (0.40-0.80)	0.63 (0.24-1.67)	0.71 (0.52-0.96)	0.24 (0.13-0.41)	0.29 (0.16-0.51)	0.47 (0.30-0.73)
Titer ≥1:40	0.25 (0.10-0.63)	0.54 (0.06-5.30)	0.38 (0.15-0.94)	0.02 (0.003-0.18)	0.09 (0.02-0.39)
A/Wyoming^d								
Log scale	0.62 (0.45-0.84)	0.94 (0.43-2.03)	0.76 (0.58-0.99)	0.38 (0.26-0.56)	0.37 (0.24-0.57)	0.48 (0.32-0.72)
Titer ≥1:40	0.32 (0.14-0.73)	1.66 (0.23-12.08)	0.49 (0.22-1.10)	0.13 (0.05-0.34)	0.08 (0.02-0.34)
A/Wisconsin^e								
Log scale	...	0.95 (0.48-1.90)	0.67 (0.39-1.13)	0.54 (0.19-1.49)	0.65 (0.40-1.06)	...
Titer ≥1:40	...	1.19 (0.24-5.79)	0.28 (0.06-1.32)	0.47 (0.13-1.69)	...
B/Shanghai^d								
Log scale	...	0.26 (0.03-2.27)	0.57 (0.26-1.22)	0.48 (0.23-1.01)	...
Titer ≥1:40	0.14 (0.02-1.20)	...
B/Brisbane^f								
Log scale	0.70 (0.39-1.27)	...	0.71 (0.39-1.29)	0.46 (0.23-0.93)	0.51 (0.26-1.01)	0.47 (0.21-1.06)
Titer ≥1:40	0.66 (0.15-2.96)	...	0.60 (0.11-3.11)	0.11 (0.01-0.91)	0.12 (0.01-1.01)

Abbreviations: ellipsis, analysis could not be performed; HI, hemagglutinin inhibition.

^aLog scale analysis is based on a continuous scale. Relative risk is the risk of influenza outcome for each log scale increase in cord blood antibody titer. Titer ≥1:40 analysis compares the risk of influenza outcome among those with a cord blood titer of 1:40 or greater with the risk among those with a titer of less than 1:40.

^bCirculating strain during 2002-2003 season.

^cVaccine strains for the 2002-2003 and 2003-2004 seasons.

^dVaccine strains for the 2004-2005 season.

^ePredominating influenza A H3N2 virus for 2004-2005 season.

^fPredominating influenza B virus for 2003-2004 season.

1 outpatient ILI episode in addition to their ILI that required hospitalization), 412 (36%) had only outpatient ILI, and 555 (48%) had no medically attended ILI episodes. The ILI incidence rate was 7.2 per 1000 person-days and 6.7 per 1000 person-days for infants born to unvaccinated and vaccinated women, respectively (our article on epidemiology is in preparation).

MATERNAL INFLUENZA VACCINATION AND PROTECTION FROM INFECTION

Fifty-two percent (n=605) of infants had an ILI, of which 14% (83) were laboratory-confirmed influenza. Ten of the laboratory-confirmed influenza virus infections were confirmed by virus culture, 71 by serology, and 2 by positive rapid influenza diagnostic testing. The mean infant age at first ILI was 47 days (median, 41; range, 0-175) and did not differ between infants born to vaccinated and unvaccinated mothers.

We found a 41% reduction in the risk of laboratory-confirmed influenza virus infection (relative risk [RR], 0.59; 95% confidence interval, 0.37-0.93) for infants of influenza-vaccinated mothers compared with infants of unvaccinated mothers (**Table 2**). A significant reduction in influenza virus infection risk was also observed with increasing cord blood HI antibody titers (log scale) (RR range, 0.42-0.68) and among children with HI antibody titers of 1:40 or greater compared with those

with titers of less than 1:40 (RR range, 0.14-0.54) for all 8 virus strain antigens (Table 2). When the analysis was restricted to serologically confirmed influenza virus infection, there was a significant association between increasing cord blood titers and decreasing risk of influenza virus infection (**Table 3**). This finding was observed for all 8 virus strains, although only statistically significant for A/NewCal (H1N1), A/Panama (H3N2), A/Wyoming (H3N2), B/Sichuan, and B/Brisbane.

No statistically significant associations were found between maternal influenza vaccination status or influenza strain-specific cord blood HI antibody titers and ILI occurrence (Table 2). However, when the outcome was restricted to ILI requiring hospitalization, a 39% reduction in risk was found (RR, 0.61; 95% confidence interval, 0.45-0.84) for infants born to influenza-vaccinated mothers compared with those of unvaccinated mothers. Among infants who had an ILI, those born to influenza-vaccinated mothers had a 42% reduction in the risk of the ILI resulting in hospitalization (RR, 0.58; 95% confidence interval, 0.41-0.83) compared with infants born to unvaccinated mothers.

We found no statistically significant associations between smoking in the household, daycare attendance of household children, a wood- or coal-burning stove, or infant breastfeeding and the occurrence of any of the outcomes (data not shown). Therefore, we did not adjust the univariate regression models by these factors as originally planned.




Figure. Geometric mean titers of strain-specific influenza hemagglutinin inhibition antibodies by vaccination status of the mother. Bars around each point on each figure indicate 95% confidence intervals; * $P < .001$; †Circulating strain during 2002-2003 season; ‡Vaccine strains for the 2002-2003 and 2003-2004 seasons; §Vaccine strains for the 2004-2005 season; ||Predominating influenza A H3N2 virus for 2004-2005 season; ¶Predominant influenza B virus for 2003-2004 season.

INFLUENZA HI GMTS

Hemagglutinin inhibition antibody GMTs to each of the 8 influenza virus antigens tested in the postpartum, cord, and 2- to 3-month infant blood were significantly higher in infants born to influenza-vaccinated compared with unvaccinated mothers. However, no differences were

found in the GMTs of HI antibody titers at 6 months of age between the 2 groups, with the exception of B/Sichuan and B/Brisbane (**Figure**).

A significantly higher proportion of subjects in the vaccinated group had HI antibody titers of 1:40 or greater against each of the 8 influenza viruses than the unvaccinated group for postpartum and cord blood (eTable;

Table 4. GMT of Influenza-Specific Hemagglutinin Inhibition Antibody Titers in Cord Blood by Influenza Virus Strain and Trimester of Immunization

Influenza Virus Strain	Timing of Influenza Vaccination During the Mother's Pregnancy						GMT <i>P</i> Value ^a	% <i>P</i> Value ^b
	Second Trimester			Third Trimester				
	Sample, No.	GMT (95% CI)	Titer >1:40, %	Sample, No.	GMT (95% CI)	Titer >1:40, %		
B/Sichuan ^c	60	45.4 (32.0-64.4)	58.3	267	55.3 (46.8-65.4)	67.5	.26	.17
B/HK ^d	92	16.2 (12.6-20.8)	30.4	192	18.8 (15.8-22.3)	42.5	.26	.05
A/New Cal (H1N1) ^{d,e}	123	45.8 (35.5-59.0)	61.0	390	58.7 (50.3-68.5)	69.6	.09	.08
A/Panama (H3N2) ^d	60	63.5 (48.2-83.6)	80.0	267	71.5 (61.4-83.4)	77.6	.49	.69
A/Wyoming (H3N2) ^e	60	43.4 (32.5-57.8)	65.0	267	55.4 (46.8-65.6)	69.4	.18	.51
A/Wisconsin (H3N2) ^f	63	11.4 (8.8-14.7)	14.3	123	12.5 (10.3-15.1)	22.0	.61	.21
B/Shanghai ^e	63	51.0 (36.0-72.2)	66.7	123	57.4 (45.3-72.7)	70.7	.57	.57
B/Brisbane ^g	31	58.5 (37.9-90.3)	71.0	197	63.9 (52.6-77.6)	73.1	.63	.80

Abbreviations: CI, confidence interval; GMT, geometric mean titer.

^aWilcoxon rank sum test.

^b χ^2 test.

^cCirculating strain during 2002-2003 season.

^dVaccine strains for the 2002-2003 and 2003-2004 seasons.

^eVaccine strains for the 2004-2005 season.

^fPredominating influenza A H3N2 virus for 2004-2005 season.

^gPredominating influenza B virus for 2003-2004 season.

www.archpediatrics.com). The actual percentages and differences varied by influenza virus strain. For A/Wisconsin, only 3% and 7% of the postpartum and cord blood HI antibody titers, respectively, were 1:40 or greater compared with 12% and 19% for the vaccinated group. For A/Panama, the percentage of unvaccinated subjects with postpartum and cord blood HI antibody titers of 1:40 or greater were 37% and 41%, respectively, compared with 78% and 79% for the vaccinated group. This was also true for infants' 2- to 3-month sera, with the exception of B/HK (unvaccinated group ranged from 2% [A/Wisconsin] to 17% [A/Panama]; vaccinated group, 4% [A/HK] to 32% [A/Panama]). At 6 months, no significant differences were found in the percentage of infants with HI antibody titers of 1:40 or greater for any of the 8 influenza virus strains between infants born to influenza-vaccinated and unvaccinated mothers (eTable).

MATERNAL INFLUENZA VACCINATION TIMING

Of the 522 influenza-vaccinated mothers with a cord blood specimen, 123 were vaccinated in the second trimester and 390 in the third trimester. For all 8 influenza virus strains, there was no difference in the cord blood titers (GMTs or proportion with titers 1:40 or greater) according to trimester of vaccination (**Table 4**).

COMMENT

This prospective study demonstrated that maternal influenza vaccination was associated with a 41% reduced risk of laboratory-confirmed influenza virus infection and a 39% reduced risk of ILI hospitalization among the infants born to these mothers. The ILI incidence rate among infants of unimmunized mothers was 7.2 per 1000 person-days of observation; 9% of infants born to unimmunized mothers had laboratory-confirmed influenza vi-

rus infection in the first 6 months of life, a proportion comparable with the 10% seen in a randomized trial of maternal influenza vaccination in Bangladesh.¹⁴

The mechanism of reduced influenza virus infection risk in infants of vaccinated mothers could include reduced influenza exposure of the infant from the mother, increased protection of the infant following exposure through increased transplacentally acquired antibody titers, or residual confounding not controlled for in the study. We did not evaluate maternal illness patterns during or following pregnancy but did evaluate influenza strain-specific antibody status of the infants and the correlation between these antibodies and influenza virus infection. We found significantly higher influenza HI antibody titers in infants born to women vaccinated during pregnancy compared with infants of unvaccinated mothers at 2 to 3 months of age and demonstrated a correlation with a reduced risk of influenza virus infection in young infants with higher antibody titers. These findings are consistent with the serologic data from the Bangladesh clinical trial.²⁰

Findings from previous studies are inconsistent about the effects of maternal influenza antibody levels or vaccination on infant outcomes. Together, 3 prospective US-based observational studies concluded that higher infant influenza antibody titers delay the age at first infection and decrease the severity of influenza illness but could not identify a reduced risk of illness episodes.^{12,13,21} This last observation, which was also seen in a cohort study by France et al,²² may be attributable to the lack of laboratory confirmation and use of nonspecific clinical outcomes for influenza. A recent prospective, randomized study conducted in Bangladesh investigated the association between maternal influenza vaccination and protection from influenza illness in infants. Infants born to influenza-vaccinated mothers were 63% and 29% less likely to have illness defined by a positive result on a rapid

influenza diagnostic test and febrile respiratory illness, respectively, compared with infants in the control group.¹⁴

There are several limitations to our study. We investigated mother-infant characteristics that could confound the findings and found no associations with vaccination or outcome; however, there is always the possibility of uncontrolled residual confounding. Furthermore, the study was conducted during 3 relatively mild influenza seasons. Although we only identified a small number of culture-confirmed influenza illnesses, we serologically identified many additional infants with influenza. Serologic detection is not 100% sensitive for influenza virus infection; however, assuming the sensitivity does not vary according to maternal vaccination status, any lack of sensitivity would reduce the power for detecting a difference. If the sensitivity of detecting rising antibody titers is lower in infants of vaccinated than unvaccinated mothers, which could occur as a result of falling passively acquired antibodies, then the odds ratio would be overestimated. We do not believe this is a significant issue because of the interval of blood drawing and the rate of declining antibodies. Serological data strengthened our findings and indicated that influenza HI antibodies in cord blood and infant sera up to 2 to 3 months of age provided protection against laboratory-confirmed, clinically apparent, mild, and asymptomatic influenza virus infections. Investigation of these associations during more severe seasonal or pandemic epidemics may add to and further enhance these associations.

This study found that influenza vaccination of pregnant women was significantly associated with increased influenza antibody titers in their infants through 2 to 3 months of age and protection from influenza virus infection and ILI hospitalization during the first 6 months of life. Although influenza vaccination is recommended for pregnant women to reduce their risk of influenza complications, these findings provide support for the added benefit of protecting infants from influenza virus infection up to 6 months, the period when infants are not eligible for influenza vaccination but are at highest risk of severe influenza illness. These findings are particularly relevant with the emergence of 2009 pandemic influenza A (H1N1) virus, which had a substantial effect on pregnant women and high hospitalization rates among young infants.^{23,24} The 2009 H1N1 virus strain is included as a component of the 2010 Southern and 2010-2011 Northern Hemisphere seasonal trivalent influenza vaccines.²⁵⁻²⁷ The findings of this study underscore the public health importance of maternal influenza vaccination to prevent influenza in both pregnant women and their infants.^{23,24}

Accepted for Publication: July 29, 2010.

Published Online: October 4, 2010. doi:10.1001/archpediatrics.2010.192. This article was corrected on October 5, 2010.

Correspondence: Katherine L. O'Brien, MD, MPH, Center for American Indian Health, 621 N Washington St, Baltimore, MD 21205 (klobrien@jhsph.edu).

Author Contributions: Drs O'Brien and Eick had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. *Study concept and design:* Uyeki, Klimov,

Santosham, and O'Brien. *Acquisition of data:* Eick, Uyeki, Klimov, and Reid. *Analysis and Interpretation of data:* Eick, Uyeki, Klimov, Hall, and O'Brien. *Drafting of the manuscript:* Eick, Uyeki, and O'Brien. *Critical revision of the manuscript for important intellectual content:* Eick, Uyeki, Klimov, Hall, Reid, Santosham, and O'Brien. *Statistical analysis:* Eick. *Obtained funding:* Uyeki and O'Brien. *Administrative, technical, or material support:* Eick, Uyeki, Hall, Reid, and O'Brien. *Study supervision:* Eick, Klimov, and O'Brien.

Financial Disclosure: Dr O'Brien reports receiving grants for research projects unrelated to this article from MedImmune and Pfizer and serving on expert advisory committees for pneumococcal vaccines from Sanofi-Pasteur; all 3 manufacture influenza vaccine.

Funding/Support: The study was funded by the National Vaccine Program Office, Department of Health and Human Services, the Office of Minority Women's Health, Centers for Disease Control and Prevention, Aventis-Pasteur, and Evans-Powderject.

Role of the Sponsor: The funding organizations had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

Disclaimer: The views expressed are those of the authors and do not necessarily reflect the policies of the Centers for Disease Control and Prevention or the Indian Health Service.

Online-Only Material: The eTable is available at <http://www.archpediatrics.com>.

Additional Contributions: The authors thank the field workers, nurses and staff of the Center for American Indian Health for their dedicated work on the Maternal Influenza Study from which these data were collected, as well as the families who participated in this study for their commitment to this project and to the health of their tribes.

REFERENCES

1. Glezen WP, Decker M, Joseph SW, Mercready RG Jr. Acute respiratory disease associated with influenza epidemics in Houston, 1981-1983. *J Infect Dis*. 1987; 155(6):1119-1126.
2. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. *JAMA*. 2004;292(11):1333-1340.
3. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. *N Engl J Med*. 2000;342(4):232-239.
4. Fiore AE, Shay DK, Broder K, et al; Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. *MMWR Recomm Rep*. 2009;58(RR-8):1-52.
5. Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infections in infants. *Pediatr Infect Dis J*. 1997;16(11):1065-1068.
6. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. *N Engl J Med*. 2000;342(4):225-231.
7. Bhat N, Wright JG, Broder KR, et al; Influenza Special Investigations Team. Influenza-associated deaths among children in the United States, 2003-2004. *N Engl J Med*. 2005;353(24):2559-2567.
8. Louie JK, Schechter R, Honarmand S, et al. Severe pediatric influenza in California, 2003-2005: implications for immunization recommendations. *Pediatrics*. 2006;117(4):e610-e618.
9. Coffin SE, Zaoutis TE, Rosenquist AB, et al. Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza. *Pediatrics*. 2007;119(4):740-748.
10. Schrag SJ, Shay DK, Gershman K, et al; Emerging Infections Program Respira-

- tory Diseases Activity. Multistate surveillance for laboratory-confirmed, influenza-associated hospitalizations in children: 2003-2004. *Pediatr Infect Dis J*. 2006; 25(5):395-400.
11. Moore DL, Vaudry W, Scheifele DW, et al. Surveillance for influenza admissions among children hospitalized in Canadian immunization monitoring program active centers, 2003-2004. *Pediatrics*. 2006;118(3):e610-e619.
 12. Reuman PD, Ayoub EM, Small PA. Effect of passive maternal antibody on influenza illness in children: a prospective study of influenza A in mother-infant pairs. *Pediatr Infect Dis J*. 1987;6(4):398-403.
 13. Puck JM, Glezen WP, Frank AL, Six HR. Protection of infants from infection with influenza A virus by transplacentally acquired antibody. *J Infect Dis*. 1980;142(6):844-849.
 14. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants [correction appears in *N Engl J Med*. 2009;360(6):648]. *N Engl J Med*. 2008;359(15):1555-1564.
 15. Lowther SA, Shay DK, Holman RC, Clarke MJ, Kaufman SF, Anderson LJ. Bronchiolitis-associated hospitalizations among American Indian and Alaska Native children. *Pediatr Infect Dis J*. 2000;19(1):11-17.
 16. Peck AJ, Holman RC, Curns AT, et al. Lower respiratory tract infections among American Indian and Alaska Native children and the general population of U.S. Children. *Pediatr Infect Dis J*. 2005;24(4):342-351.
 17. Bockova J, O'Brien KL, Oski J, et al. Respiratory syncytial virus infection in Navajo and White Mountain Apache children. *Pediatrics*. 2002;110(2 pt 1):e20.
 18. Wootton SH, Scheifele DW, Mak A, Petric M, Skowronski DM. Detection of human influenza virus in the stool of children. *Pediatr Infect Dis J*. 2006;25(12):1194-1195.
 19. Tuyishime JD, De Wals P, Moutquin JM, Frost E. Influenza-like illness during pregnancy: results from a study in the eastern townships, Province of Quebec. *J Obstet Gynaecol Can*. 2003;25(12):1020-1025.
 20. Steinhoff MC, Omer SB, Roy E, et al. Influenza immunization in pregnancy: antibody responses in mothers and infants. *N Engl J Med*. 2010;362(17):1644-1646.
 21. Black SB, Shinefield HR, France EK, Fireman BH, Platt ST, Shay D; Vaccine Safety Datalink Workgroup. Effectiveness of influenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants. *Am J Perinatol*. 2004;21(6):333-339.
 22. France EK, Smith-Ray R, McClure D, et al. Impact of maternal influenza vaccination during pregnancy on the incidence of acute respiratory illness visits among infants. *Arch Pediatr Adolesc Med*. 2006;160(12):1277-1283.
 23. Louie JK, Acosta M, Jamieson DJ, Honein MA; California Pandemic (H1N1) Working Group. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. *N Engl J Med*. 2010;362(1):27-35.
 24. Siston AM, Rasmussen SA, Honein MA, et al; Pandemic H1N1 Influenza in Pregnancy Working Group. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. *JAMA*. 2010;303(15):1517-1525.
 25. World Health Organization. Recommended composition of influenza virus vaccine for use in the 2010 influenza season (southern hemisphere winter). *WHO Weekly Epidemiological Record*. 2009;84:421-436.
 26. World Health Organization. Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. *WHO Weekly Epidemiological Record*. 2010;85:81-92.
 27. Gruslin A, Steben M, Halperin S, Money DM, Yudin MH; Infectious Diseases Committee of the Society of Obstetricians and Gynaecologists of Canada. Immunization in pregnancy. *J Obstet Gynaecol Can*. 2009;31(11):1085-1101.

Correction

Error in Expansion of NOURISH Trial Acronym. In the Review Article titled "Interventions Aimed at Decreasing Obesity in Children Younger Than 2 Years: A Systematic Review," by Ciampa et al, published in the December issue of the *Archives* (2010;164[12]:1098-1104), an error occurred in expanding the acronym NOURISH. On page 1102, right-hand column, "Ongoing Studies" subsection, lines 6 through 8, the NOURISH trial (ACTRN12608000056392, reference 43) acronym has no expansion.